Objectives: To assess whether the commercial ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains, IL, USA) can be used in conjunction with dried blood spots (DBS) for clinical monitoring of drug resistance in patients who fail antiretroviral treatment (ART) in rural Tanzania.
Introduction
By the end of 2008, .4 million people were receiving antiretroviral treatment (ART) of HIV/AIDS in low-and middle-income countries, which is a 10-fold expansion over the past 5 years. 1 The probability of drug resistance increases with duration of treatment and has been estimated to reach 27% by 6 years. 2 Thus, the number of individuals in need of second-line ART in low-and middle-income countries can be expected to rise sharply in the coming years.
Drug resistance testing is standard of care in industrialized countries in order to tailor new fully active regimens in patients with treatment failure, but is rarely available in resource-limited settings due to high costs and stringent requirements for storage and transport of plasma. Hence, patients with treatment failure in such settings usually switch blindly from a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen to a protease inhibitor-based regimen. However, since most patients with treatment failure are detected late, at which stage widespread resistance is common, patients risk undergoing switches to regimens with limited efficacy. Further down the line, switching blindly to a third-or fourth-line regimen will be virtually impossible without access to resistance testing.
Dried blood spots (DBS) are easy to collect and store, and can be a convenient alternative to plasma. Recently, several studies have demonstrated the feasibility and reliability of using DBS to monitor HIV drug resistance. 3 -6 However, most studies utilized in-house genotyping assays, and few used specimens collected under 'real-life' field conditions. Commercial genotyping kits have several advantages over in-house assays, including qualitycontrolled reagents, standardized protocols and validated interpretation tools, and would facilitate routine use in high-throughput settings; however, these kits have only been validated with plasma. We therefore aimed to assess the performance of the ViroSeq assay in conjunction with DBS obtained under field conditions from patients failing ART in rural Tanzania.
Patients and methods
We utilized 36 remnant DBS cards collected from patients with known treatment failure of an NNRTI-based first-line regimen at Haydom Lutheran Hospital. Median plasma viral load was 15180 copies/mL (range 1350 -3683 000), and a plasma genotype was available from all patients. HIV-1 subtypes were A (n¼11), C (n ¼10), D (n¼12) and CRF01_AE (n¼3). A more detailed description of the study population has been published previously. 7 All patients gave written consent to participate in the study, and the study was approved by the National Institute for Medical Research (Tanzania) and Regional Committee for Medical Research Ethics (Norway).
DBS were prepared by spotting whole blood from a plasma preparation tube (PPT; Becton Dickinson, Franklin Lakes, NJ, USA) onto a 903 filter paper card (Whatman plc, Maidstone, UK) to completely fill the circles. The cards were dried overnight (temperature range 24-288C) and stored in zip-lock plastic bags (purchased locally) with a silica desiccant (Elcon-Broker AS, Holmestrand, Norway). DBS were stored at the collection site at 2208C for a median of 126 days Results by the use of an in-house assay have been published previously. HIV-1 genotyping from dried blood spots 261 JAC (range 0 -203), and exposed to ambient temperature for 20 days during transport. Before shipment, desiccants were replaced with new ones, after allowing the DBS to equilibrate at room temperature for a minimum of 1 h. After arrival at the reference laboratory (Hospital Carlos III, Madrid, Spain), samples were kept at 2208C until processing 1 month later. Total nucleic acids were extracted from two circles of dried blood, each of which holds 75-80 mL of whole blood, 8 using the NucliSENS silica-based extraction method (bioMérieux, Inc., Durham, NC, USA) as described previously. 7 HIV-1 genotypic analysis was done using the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Des Plains, IL, USA) following the manufacturer's instructions. This method amplifies the entire protease gene and approximately two-thirds of the reverse transcriptase (RT) gene, representing 1.8 kb of HIV-1 pol. The assay is performed by a single RT-PCR and has a sensitivity of detection of 2000 HIV-1-RNA copies/mL in plasma.
Genotypes obtained with DBS were compared with those obtained with use of a plasma-based assay. Plasma was genotyped using the ViroSeq HIV-1 Genotyping System v2.0 with inclusion of an in-house RT-nested PCR step as previously described. 7 Resistance profiles to antiretroviral drugs were interpreted according to the Stanford University HIV Drug Resistance Database (HIVdb Program, http://hivdb.stanford.edu). Only drug resistance mutations listed in the December 2009 update from the International AIDS Society were considered in the present study. 9 Logistic regression was used to study factors associated with amplification failure. Data were analysed with SPSS v16.0 for Windows (SPSS Inc., Chicago, IL, USA). All tests were two-sided and the level of significance was set at P,0.05.
Results
HIV-1 pol was successfully amplified in 17 of 36 (47%) DBS specimens using the ViroSeq assay, but one of these yielded a genotype in the protease region only ( Table 1) . Most of the amplification failures occurred in specimens with low-level viraemia. Only 2 of 16 (13%) DBS with a viral load of ,10 000 copies/ mL could be amplified, compared with 15 of 20 (75%) DBS with a viral load of .10 000 copies/mL (P ¼ 0.001). Amplification failures were observed with all HIV-1 subtypes in the study population: A (n¼ 6); C (n¼ 6); D (n¼ 5); and CRF01_AE (n¼ 2). In specimens with viral loads of .10 000 copies/mL, four of five amplification failures were subtype A; however, numbers were small and not statistically significant. Furthermore, there was no significant association between the length of DBS storage at 2208C and amplification failure (P ¼ 0.70).
Seventeen plasma/DBS pairs were available for comparison (Table 2 ). Of 77 protease mutations found in plasma, 70 (91%) were also detected in DBS, all of which were minor mutations or polymorphisms. The seven protease mutations missed in DBS were present in plasma as mixtures with the wild-type strain. No additional protease mutations were observed in DBS. In the RT region, all 23 clinically significant mutations in plasma were also detected in DBS. In addition, one RT mutation was found in DBS only, as a mixture in the 101 position (K101EK in patient 13) with some impact on etravirine resistance I13V, M36I, D60E, I64V  I13V, M36I, D60E, I64V  none  none  2  I13V, K20R, M36MV, L63P, I64V,  I93IL   I13V, K20R, L63P, I64V  G190A  G190A   3  M36I, L63LP, H69K, I93L  M36I, L63LP, H69K, I93L  K103N, E138A  K103N, E138A  4  M36I, L63P, H69K, I93L  M36I, L63P, H69K, I93L  none  none  6  G16E, H69K, V77I, I93L  G16E, H69K, V77I, I93L  K103N, V108IV, M184V, P225H  K103N, V108IV, M184V, P225H  7  I13V, K20R, M36MI, I62IV, I64V  I13V, K20R, I62IV, I64V  none  none  8  L10IV, I13IV, G16GE, I62V, I64V,  V77I, I85IV   L10IV, G16E, I62V, I64V,  V77I   M184V, G190A  M184V, G190A   10  I13V, M36I, L63P, I64V, H69K, V77I I13V, M36I, L63P, I64V,  H69K, V77I   K103KN  K103KN   11  M36I, H69K, I93L  M36I, H69K, I93L  none  none  12  I13V, M36I, L63P, H69K  I13V, M36I, L63P, H69K  D67N, K70R, K103N, V179TV,  M184V, K219Q   D67N, K70R, K103N, V179T,  M184V, K219Q  13  I13V, M36I, L63LP, H69K, V82VI  I13V, M36I, H69K, V82IV  V179T, M184V, G190A  K101EK, V179T, M184V, G190A  14  I13V, M36I, H69K  I13V, M36I, H69K  none  none  15  L10V, I13V, G16E, M36I, I62IV,  H69K   L10V, I13V, G16E, M36I,  H69K   E138A  E138A   19  I13V, M36I, D60E, L63P, H69K  I13V, M36I, D60E, L63P,  H69K   none  none   20  L63P, V77VI  L63LP, V77IV  none  none  22  I13V, L63P, I64V, V77I  I13V, L63LP, I64V, V77I  K101E, M184V, G190A  K101E, M184V, G190A  25  I13V, K20R, M36I, I62IV, I64IV  I13V, K20R, M36I, I62V,  I64IV none failed
Discordances between plasma and DBS are underlined. Discordances that represent drug-resistant mutations are bold and underlined.
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interpretation. Thus, 16 of 17 (94%) patients had identical resistance profiles to antiretroviral drugs in plasma and DBS. The whole sequence of 1302 bases was compared between plasma and DBS, with mixed bases being classified as different. Mean nucleotide similarity was 98.7% (SD 0.62), ranging from 97.5% to 99.7%.
DBS genotypes obtained with the ViroSeq assay were highly concordant with those obtained with use of a previously published in-house DBS method. 7 Of 94 mutations found with the ViroSeq assay, 88 (93.6%) were also detected with the in-house assay, and vice versa.
Discussion
The ViroSeq kit successfully genotyped approximately half of DBS specimens from patients with ART failure in rural Tanzania. Although efficient in patients with high viral loads, the ViroSeq kit failed to genotype most DBS specimens with viral loads of ,10 000 copies/mL. In the specimens that yielded a genotype, however, there was high concordance with results from a plasma-based assay.
Three previous studies have assessed the ViroSeq kit in conjunction with DBS. Masciotra et al. 4 successfully genotyped all DBS with viral loads of .2000 copies/mL, compared with 55% of those with viral loads of ,2000 copies/mL. Youngpairoj et al. 5 reported that only 8% of DBS could be genotyped when viral load was ,10 000 copies/mL, compared with 81% when viral load was .10000 copies/mL, similar to our results. Finally, in a recent study from Mexico, Lira et al. 10 successfully genotyped 60% of DBS with viral loads of .14000 copies/mL, but none of the DBS with viral loads below this level. All these studies found high concordance between nucleotide sequences derived from DBS and plasma, in line with our findings. Our study, however, is the first to assess the ViroSeq kit with DBS from patients infected with non-B subtypes. The ViroSeq kit was originally optimized for HIV-1 subtype B; 11 hence, future DBS studies should aim to include various subtypes, including subtype A, which frequently failed amplification in our study, even in specimens with high viral loads.
Previously, we reported 94% amplification success from DBS collected in duplicate with DBS utilized in the present study and stored under less favourable conditions, using an in-house RT-nested PCR method. 7 Youngpairoj et al. 5 reported similar results; overall amplification success was 57.5% with the ViroSeq kit and 95% with an in-house nested assay. In-house assays typically reduce the costs by .50% compared with commercial kits. 12 Furthermore, the use of a nested PCR protocol appears to increase sensitivity, particularly in samples with low-level viraemia, such as patients with early treatment failure. However, in resource-limited settings, where the selection of second-line antiretroviral drugs is scarce, the WHO recommends that first-line treatment be conserved as long as viral load does not exceed 10 000 copies/mL. 13 Thus, the ViroSeq kit in conjunction with DBS could be an acceptable option for resistance testing under the WHO guidelines, given that genotyping is restricted to patients who reach the viral load threshold for regimen switch. Nonetheless, further refinement of the ViroSeq kit with DBS is warranted in order to increase sensitivity.
Our study was limited by a relatively small sample size. Moreover, although DBS and plasma were both genotyped using the ViroSeq kit, the use of different amplification methods might have contributed to discordances between the two specimen types. The main strength of our study was that we used samples obtained in rural Africa, and we believe our results reflect 'real-life' performance of DBS-based resistance monitoring in the field. However, temperature and humidity conditions differ from place to place, and the effect of various storage conditions should be studied in more detail.
In conclusion, we found that the ViroSeq kit performed well using DBS from patients with major virological failure, but failed to genotype most DBS with viral loads of ,10000 copies/mL. In DBS samples that yielded a genotype, there was high concordance between mutations found in DBS and plasma. Using the WHO guidelines for ART in resource-limited settings, recommending regimen switch only in patients with viral loads of .10000 copies/mL, the ViroSeq kit in conjunction with DBS could be an acceptable option for drug resistance testing.
